Our telehealth services are available to patients located in all 50 U.S. states and the District of Columbia. All consultations are conducted by licensed U.S. healthcare providers, and all prescriptions are dispensed by licensed U.S. pharmacies. Treatment is only provided where clinically appropriate and permitted by applicable state and federal law. Availability of specific medications may vary by state based on state regulations and provider licensure.
Asynchronous (online questionnaire) care is available in the following 44 states: AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KY, MA, MD, ME, MI, MN, MO, MT, NC, ND, NE, NH, NJ, NV, NY, OH, OK, OR, PA, SC, SD, TN, TX, UT, VA, VT, WA, WI, WY. A live (synchronous) consultation with a provider is required before treatment in these 7 jurisdictions: District of Columbia (DC), Kansas (KS), Louisiana (LA), Mississippi (MS), New Mexico (NM), Rhode Island (RI), West Virginia (WV).
Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs, and arms in the first month. Patients exercised daily and ate a reduced-calorie diet. Their fat loss is not typical. Results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Based on self-reported data from Valeon patients on a compounded GLP-1 program, some patients report approximately 1–2 lb per week of weight loss after the first 4 weeks when combined with a reduced-calorie diet and increased physical activity. Individual results vary substantially; many patients will lose less. Compounded medications are not FDA-approved. Consult a healthcare professional before using medication or starting any weight loss program. Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.
Medication is included in the cost of the Valeon Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy®, Ozempic®), and products displayed on this Internet site are protected and belong to their respective owners. Medical treatment is provided by “CareGLP Affiliated P.C.s” and Valeon affiliated networks for medical professional corporations and associations. No data, photos, claims, or any other information are associated with results derived from clinical trials, studies, or public information and is always representative of Valeon patient experience.
Certain materials on this website, including text, images, and other media, may be generated or enhanced using artificial intelligence technologies. No representation or warranty is made regarding the accuracy, completeness, or reliability of such content. Individuals appearing in advertisements may be actors or AI portraying doctors and are not licensed medical professionals.
Testimonials on the website are from Valeon patients. For patient privacy, images representing those testimonials may use models or AI.